Favorable predictors for survival in advanced ALK ‐positive non‐small cell lung cancer patients beyond crizotinib resistance-Reference-Cited by-同舟云学术

Favorable predictors for survival in advanced ALK ‐positive non‐small cell lung cancer patients beyond crizotinib resistance

Published:2019-03-28 Issue:5 Volume:10 Page:1096-1102
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Xu Haiyan¹^ORCID,Yang Guangjian²,Yang Lu²^ORCID,Yang Yaning²,Ma Di²^ORCID,Li Junling²,Hao Xuezhi²,Xing Puyuan²,Wang Yan²

Affiliation:

1. Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China

2. Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer /Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13050

Reference20 articles.

1. Lung Cancer Statistics

2. Cancer statistics, 2018

3. Histological subtypes of lung cancer in Chinese males from 2000 to 2012;Zou XN;Biomed Environ Sci,2014

4. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

5. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center;Frontiers in Oncology;2019-10-22